HC Wainwright Begins Coverage on Autolus Therapeutics (NASDAQ:AUTL)

Stock analysts at HC Wainwright started coverage on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note issued to investors on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $9.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 476.92% from the company’s previous close. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.04) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.64) EPS and FY2030 earnings at ($0.24) EPS.

A number of other research firms also recently issued reports on AUTL. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. Zacks Research cut Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 21st. Needham & Company LLC dropped their target price on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, January 12th. Finally, Wall Street Zen downgraded Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.50.

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $1.56 on Tuesday. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $2.70. The firm has a market capitalization of $415.18 million, a PE ratio of -1.88 and a beta of 1.98. The stock’s 50-day simple moving average is $1.57 and its 200-day simple moving average is $1.57.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL increased its position in shares of Autolus Therapeutics by 36.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 282,113 shares of the company’s stock worth $561,000 after purchasing an additional 75,460 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Autolus Therapeutics by 12.2% in the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after purchasing an additional 1,900,000 shares in the last quarter. Cetera Investment Advisers raised its position in shares of Autolus Therapeutics by 37.3% during the 4th quarter. Cetera Investment Advisers now owns 1,099,750 shares of the company’s stock worth $2,189,000 after acquiring an additional 298,500 shares in the last quarter. Mak Capital One LLC lifted its position in shares of Autolus Therapeutics by 15.3% during the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after buying an additional 3,987,727 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Autolus Therapeutics by 29.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 49,864 shares of the company’s stock valued at $99,000 after acquiring an additional 11,445 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

More Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy”/”Strong-Buy” and a $9.00 price target — a very large implied upside versus the current share price; this kind of initiation can attract momentum buyers and re-rate sentiment for a beaten-down biotech. Read More.
• Positive Sentiment: HC Wainwright published detailed EPS forecasts across FY2025–FY2030 and quarter-level EPS estimates (showing shrinking losses over time), reinforcing their view that Autolus’ pipeline and commercialization path could improve economics over the next several years — supportive for long-term bulls. Read More.
• Neutral Sentiment: Short-interest data for mid-February in the report appears to show zeros/NaN (likely a reporting anomaly) and therefore does not provide clear evidence of elevated short pressure driving the move.
• Negative Sentiment: Risks remain — the $9 target implies very large upside and may be optimistic given current cash burn, clinical/regulatory uncertainties and likely need for future financing; those factors could dilute shareholders or cause volatility if progress stalls.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.